<DOC>
	<DOCNO>NCT02036255</DOCNO>
	<brief_summary>The objective study investigate whether substitution standard lock solution lock solution contain taurolidine urokinase weekly ( Taurolock â„¢ U 25,000 - www.taurolock.com ) reduce rate catheter dysfunction hemodialysis patient history TCC dysfunction require urokinase therapy .</brief_summary>
	<brief_title>Prevention Dialysis Catheter Malfunction With Prophylactic Use Taurolidine Containing Urokinase</brief_title>
	<detailed_description />
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Taurolidine</mesh_term>
	<criteria>Adult , prevalent hemodialysis patient Informed consent Hemodialysis 3x/week via tunnel cuffed catheter Urokinase administration least two time previous 6 month ( week 2 administration ) Adequate catheter function week inclusion ( define blood flow 250ml/min dialysis session blood flow within 15 % maximal blood flow last Urokinase administration ) Presence heparininduced thrombocytopenia Major hemorrhage intracranial bleed previous 3 month Pericarditis Intolerance Taurolidine , citrate Urokinase Active catheterrelated infection Catheter femoral vein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention , Thrombosis , Hemodialysis , Vascular access device</keyword>
</DOC>